Table 2

Prevention of breast cancer after delayed administration of Arz and LG268

TreatmentaNo. of tumor-free rats/total no. of rats (P1; P2)bAverage no. of tumors (P1; P2)ATBc (P1; P2)Rats with 3 or more tumors (P1; P2)Rats with tumor burden > 5 g (P1; P2)
Control (vehicle)0/183.910.115/1814/18
1 week after NMU injection
 Arz (10)d9/12 (<0.0001)0.3 (0.001)0.2 (0.0005)0/12 (<0.0001)0/12 (<0.0001)
 LG268 (50)6/12 (0.002)0.8 (0.0005)0.5 (0.0005)1/12 (<0.0001)0/12 (<0.0001)
 Arz + LG26810/12 (<0.0001; 1.0)0.2 (0.0005; 0.8)0.1 (0.0005; 0.8)0/12 (<0.0001; ns)0/12 (<0.0001; ns)
5 weeks after NMU injection
 Arz (10)0/122.1 (0.02)4.04/12 (0.009)4/12 (0.02)
 LG268 (50)4/12 (0.02)1.3 (0.003)2.7 (0.01)2/12 (0.0005)3/12 (0.008)
 Arz + LG2685/11 (0.004; 0.01)0.8 (0.003; 0.1)1.2 (0.01; 0.04)1/11 (0.0003; 0.3)1/11 (0.0005; 0.3)
  • a All animals (21 days old) were given an i.p. injection of 50 mg NMU/kg body weight. They were then started on chemopreventive agents, either 1 week or 5 weeks after NMU.

  • b P1 is the value for the comparison of rats treated with chemopreventive agents with control rats treated with vehicle alone; P2 is the value for the comparison of rats treated with Arz + LG268 with rats treated with Arz alone. ns, not significant.

  • c ATB, average tumor burden (average weight in grams of a rat’s tumor at autopsy).

  • d All doses are shown as mg/kg diet.